Copyright © 1999 by the European Society of Cardiology.
Plasma N-terminal pro-brain natriuretic peptide and the ECG in the assessment of left-ventricular systolic dysfunction in a high risk population
Department of Medicine and Therapeutics, University of Leicester, Leicester, U.K.
revised May 4, 1999; accepted May 5, 1999
Abstract
Aims To examine the value of N-terminal pro-brain natriuretic peptide, abnormal electrocardiogram and other baseline clinical and laboratory variables in identifying patients with left ventricular systolic dysfunction in a high risk population.
Methods and Results We studied 243 patients (129 male, median age 73 years, range 20–94) referred for echocardiography. The relationship between left ventricular wall motion index and log N-terminal pro-brain natriuretic peptide, log creatinine, electrocardiogram, age, history of hypertension, history of ischaemic heart disease, gender, valvular disease and current drug therapy was examined using regression analysis. There was a strong correlation between N-terminal pro-brain natriuretic peptide and left ventricular wall motion index for the whole population (r=–0·624, P<0·001) and in those receiving diuretic±angiotensin converting enzyme inhibitor (r= –0·661, P<0·005) and in those receiving neither (r=–0·584,P <0·005). On multiple regression analysis, log N-terminal pro-brain natriuretic peptide (P<0·001), age (P=0·015), current diuretic (P=0·002) or angiotensin converting enzyme inhibitor use (P=0·001) and male gender (P=0·026) were independently associated with a low left ventricular wall motion index. Log N-terminal pro-brain natriuretic peptide alone (R2=39%) was a better predictor of left ventricular wall motion index than any other single or combination of factors. Plasma N-terminal pro-brain natriuretic peptide>275pmoll–1predicted left ventricular wall motion index 
1·2 with a sensitivity of 93·8%, a specificity of 55% and a negative predictive value of 93%. Left ventricular function was impaired in 18/36 patients with a normal electrocardiogram, in all of whom N-terminal pro-brain natriuretic peptide was >275fmolml–1.
Conclusion Of the variables studies, N-terminal pro-brain natriuretic peptide had the strongest correlation with reduced left ventricular wall motion index. The electrocardiogram had a poor predictive value for left ventricular systolic dysfunction in this population. Plasma N-terminal pro-brain natriuretic peptide can usefully predict patients with a reduced left ventricular wall motion index in whom echocardiographic examination may be appropriate.
Key Words: Heart failure, plasma, brain natriuretic peptide, wall motion index, chemiluminescence.
f1 Correspondence: Dr L. L. Ng, Dept. of Medicine & Therapeutics, Robert Kilpatrick Clinical Sciences Building, Leicester Royal Infirmary, Leicester LE2 7LX, U.K.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Richardson, N. Freemantle, M. J. Calvert, J. G.F. Cleland, L. Tavazzi, and on behalf of the CARE-HF Study Steering Committee Predictors and treatment response with cardiac resynchronization therapy in patients with heart failure characterized by dyssynchrony: a pre-defined analysis from the CARE-HF trial Eur. Heart J., August 1, 2007; 28(15): 1827 - 1834. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Cortes, M. Rivera, A. Salvador, V. Bertomeu, F. G. de Burgos, E. Rosello-Lleti, M. Portoles, R. Paya, L. Martinez-Dolz, and V. Climent Variability of NT-proBNP plasma and urine levels in patients with stable heart failure: a 2-year follow-up study Heart, August 1, 2007; 93(8): 957 - 962. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Heart Protection Study Collaborative Group,* N-Terminal Pro-B-Type Natriuretic Peptide, Vascular Disease Risk, and Cholesterol Reduction Among 20,536 Patients in the MRC/BHF Heart Protection Study J. Am. Coll. Cardiol., January 23, 2007; 49(3): 311 - 319. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S G Ray Natriuretic peptides in heart valve disease Heart, September 1, 2006; 92(9): 1194 - 1197. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Schnabel, E. Lubos, H. J. Rupprecht, C. Espinola-Klein, C. Bickel, K. J. Lackner, F. Cambien, L. Tiret, T. Munzel, and S. Blankenberg B-Type Natriuretic Peptide and the Risk of Cardiovascular Events and Death in Patients With Stable Angina: Results From the AtheroGene Study J. Am. Coll. Cardiol., February 7, 2006; 47(3): 552 - 558. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Tschope, M. Kasner, D. Westermann, R. Gaub, W. C. Poller, and H.-P. Schultheiss The role of NT-proBNP in the diagnostics of isolated diastolic dysfunction: correlation with echocardiographic and invasive measurements Eur. Heart J., November 1, 2005; 26(21): 2277 - 2284. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Jernberg, S. James, B. Lindahl, N. Johnston, M. Stridsberg, P. Venge, and L. Wallentin Natriuretic peptides in unstable coronary artery disease Eur. Heart J., September 1, 2004; 25(17): 1486 - 1493. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Clerico and M. Emdin Diagnostic Accuracy and Prognostic Relevance of the Measurement of Cardiac Natriuretic Peptides: A Review Clin. Chem., January 1, 2004; 50(1): 33 - 50. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C Fisher, C Berry, L Blue, J J Morton, and J McMurray N-terminal pro B type natriuretic peptide, but not the new putative cardiac hormone relaxin, predicts prognosis in patients with chronic heart failure Heart, August 1, 2003; 89(8): 879 - 881. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Ruskoaho Cardiac Hormones as Diagnostic Tools in Heart Failure Endocr. Rev., June 1, 2003; 24(3): 341 - 356. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Kucher, G. Printzen, T. Doernhoefer, S. Windecker, B. Meier, and O. M. Hess Low Pro-Brain Natriuretic Peptide Levels Predict Benign Clinical Outcome in Acute Pulmonary Embolism Circulation, April 1, 2003; 107(12): 1576 - 1578. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M Bay, V Kirk, J Parner, C Hassager, H Nielsen, K Krogsgaard, J Trawinski, S Boesgaard, and J Aldershvile NT-proBNP: a new diagnostic screening tool to differentiate between patients with normal and reduced left ventricular systolic function Heart, February 1, 2003; 89(2): 150 - 154. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. W. Nielsen, T. A. McDonagh, S. D. Robb, and H. J. Dargie Retrospective analysis of thecost-effectiveness of using plasmabrain natriuretic peptide inscreening for left ventricularsystolic dysfunction in the general population J. Am. Coll. Cardiol., January 1, 2003; 41(1): 113 - 120. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. S. Mir, S. Marohn, S. Laer, M. Eiselt, O. Grollmus, and J. Weil Plasma Concentrations of N-Terminal Pro-Brain Natriuretic Peptide in Control Children From the Neonatal to Adolescent Period and in Children With Congestive Heart Failure Pediatrics, December 1, 2002; 110(6): e76 - 76. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J G J Neffke, I I Tulevski, E E van der Wall, A A M Wilde, D J van Veldhuisen, A Dodge-Khatami, and B J M Mulder ECG determinants in adult patients with chronic right ventricular pressure overload caused by congenital heart disease: relation with plasma neurohormones and MRI parameters Heart, September 1, 2002; 88(3): 266 - 270. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I I Tulevski, M Groenink, E E van der Wall, D J van Veldhuisen, F Boomsma, J Stoker, A Hirsch, J S Lemkes, and B J M Mulder Increased brain and atrial natriuretic peptides in patients with chronic right ventricular pressure overload: correlation between plasma neurohormones and right ventricular dysfunction Heart, July 1, 2001; 86(1): 27 - 30. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S Talwar, I B Squire, P F Downie, J E Davies, L L Ng;, and G F BAXTER Plasma N terminal pro-brain natriuretic peptide and cardiotrophin 1 are raised in unstable angina Heart, October 1, 2000; 84(4): 421 - 424. [Abstract] [Full Text]
|
|